Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Debt Burdens, Revenue Drop Led Pet Care App Wag! To Ch. 11 No Photo Available

Persistent unprofitability, revenue declines related to the COVID-19 pandemic, mounting debt and failed restructuring efforts led the ... (more story)

Data Privacy A Growing Concern In Bankruptcies, Panel Says No Photo Available

A panel discussion hosted by the New York City Bar Association touched on data privacy in bankruptcy cases in the wake of 23andMe’s co... (more story)

Under The Radar: Bankruptcy News You May Have Missed No Photo Available

The Chapter 11 trustee overseeing Chinese exile Miles Guo's bankruptcy won a $33 million mansion for the estate. An insolvent real est... (more story)